Surgical Menopause: Benefits, Risks and Treatment
What is surgical menopause?
Surgical menopause is the sudden decrease in ovarian hormones resulting from the surgical removal of both ovaries before natural menopause occurs. Removal of both ovaries is called bilateral oophorectomy; if the fallopian tubes are also removed, the term salpingo-oophorectomy is used. Removal of the uterus is a hysterectomy and is not the same procedure. Knowing which organs are removed during surgery is crucial for understanding the expected hormonal changes afterward.
While hormonal changes in natural menopause are mostly experienced over a transitional period, the changes in surgical menopause can be more sudden. Symptoms such as hot flashes, sleep disturbances, vaginal dryness, and changes in sexual desire may occur. Every woman's experience is different. The reason for the surgery, age, previous health status, and the treatment plan to be applied affect the process. Therefore, it is important to discuss not only the surgical recovery but also the subsequent hormonal and long-term health needs before the surgery.
Does hysterectomy mean menopause?
If the uterus has been removed but one or both ovaries have been preserved, the woman does not automatically enter surgical menopause. Menstrual bleeding stops because the uterus is absent, but the ovaries may continue to produce hormones. In this case, the absence of bleeding alone does not indicate the end of ovarian function. In some women, menopause may develop earlier than expected; symptoms and individual circumstances are evaluated as needed. Knowing the surgical report prevents misinterpretations.
Removing one ovary is not the same as removing both ovaries. The remaining ovary may continue to function. Removing only the fallopian tubes does not mean removing the ovaries. It is helpful for the patient to understand the scope of the surgery rather than simply accepting a general statement like "everything has been removed." In a menopausal evaluation , the surgical report, current symptoms, and medications being used are considered together. The need for hormone therapy is not determined solely by the presence or absence of a uterus.
Why is surgical menopause performed?
Removal of both ovaries may be considered in the treatment of certain cancers, in specific high-risk hereditary cancers, or in selected gynecological conditions. The decision is made based on the nature of the disease and available alternatives. Routine removal of healthy ovaries solely to induce menopause is not a general approach. The expected benefits of surgery must be weighed against the consequences of early hormone loss.
In some severe cases of endometriosis, comprehensive surgery may be considered, but this is not necessary for every patient and does not guarantee a complete end to all pain. Age, pain, previous treatments, and fertility plans are important factors in evaluating endometrioma and endometriosis-related surgical outcomes . The presence of ovarian cysts does not automatically necessitate the removal of both ovaries. The scope of the procedure should be justified by individual findings.
How are the benefits of surgical menopause evaluated?
The benefit mentioned in the title does not mean that menopause itself benefits everyone. The expected benefit depends on the reason for the surgery. For example, the goal might be to remove diseased tissue or to reduce the risk of cancer in certain high-risk individuals. The benefit of cancer treatment is not evaluated in the same way as the benefit of risk-reducing surgery in a healthy person. The goal of the decision should be clearly discussed.
When surgery is planned due to pain or bleeding, it is important to determine which part of the complaint originates from the uterus and which from the ovaries. The benefit of removing the uterus does not necessarily require the removal of the ovaries as well. It is helpful for the patient to ask, "What difference does removing this organ make for me?" The expected benefit, potential risks, and organ-preserving options should be explained together. Just because someone else was satisfied with the surgery does not mean the same procedure is suitable for everyone.
Removal of ovaries in cases of hereditary cancer risk.
In high-risk situations associated with specific genetic alterations like BRCA, risk-reducing surgery may be considered after expert evaluation. A family history of cancer alone does not mean everyone should have the same surgery. Genetic counseling, individual risk assessment, and detailed family history are important. The timing of surgery, fertility plans, and subsequent hormone therapy options are discussed together.
Risk-reducing surgery can significantly lower the risk of certain cancers, but it should not be said to eliminate all cancer risks. In individuals with a history of hormone-sensitive cancers, the suitability of menopausal treatment is evaluated with the relevant oncology team. ACOG and the British Menopause Society emphasize the need to consider both the benefit of risk reduction and the consequences of early hormone loss. The decision should be made through expert consultation, not solely based on a single word in a genetic report.
When do the symptoms of surgical menopause begin?
Symptoms may appear early after surgery due to the rapid decrease in ovarian hormones. Hot flashes, night sweats, sleep disturbances, fatigue, and mood changes may occur. However, postoperative pain, recovery from anesthesia, anemia, or other conditions can also contribute to similar complaints. It is not correct to automatically attribute all new symptoms to menopause.
The timing, frequency, and impact of symptoms on daily life can be recorded. For example, waking up due to night sweats requires a different assessment than being unable to sleep due to pain. If the symptoms are very intense, a consultation with the team can be arranged without waiting for a scheduled check-up. Not every woman experiences symptoms with the same severity, and mild symptoms do not mean that a long-term health assessment is unnecessary. Age and the duration of early hormone loss are also important factors.
Differences between natural menopause and surgical menopause
In natural menopause, changes in ovarian function usually develop over time. In surgical menopause, since both ovaries are removed, the decrease in hormone production can be more sudden. Furthermore, the psychological and physical effects of the surgery can be experienced simultaneously. Therefore, in addition to standard menopause information, issues related to surgical recovery, disease monitoring, and fertility should also be addressed.
| Situation | Key feature |
|---|---|
| Natural menopause | It is associated with the natural cessation of ovarian function. |
| Removal of both ovaries before menopause | It induces surgical menopause through a sudden loss of hormones. |
| Removal of the uterus, preservation of the ovaries. | The bleeding stops; hormone production may continue. |
| Removal of one ovary | The remaining ovary may continue to function. |
| Only removal of the tubes | It is not the same as having the ovaries removed. |
| Temporary ovarian suppression with medication | This is a different process than surgical removal; the likelihood of recovery varies depending on the situation. |
These distinctions are also important in choosing a treatment. A systemic estrogen plan may differ for a woman with a uterus compared to one who has had a complete uterus removal. Special circumstances, such as a history of endometriosis or cancer, require additional evaluation. Instead of simply stating "I've entered menopause," the patient explaining which procedure or treatment led to this condition is the starting point for effective counseling.
The effect of surgical menopause on bone health.
Early-onset estrogen deficiency is significant for bone loss. Individual fracture risk is assessed considering age, previous fractures, family history, body structure, medications, and other diseases. Bone density measurement may be planned if deemed necessary. It is not mandatory for every patient to undergo testing at the same intervals. Monitoring is tailored to the initial risk and the treatment administered.
Regular, appropriate exercise, adequate nutrition, and avoiding smoking support bone health. Calcium and vitamin D requirements should be assessed according to individual circumstances; uncontrolled use of high-dose products does not provide increased protection. In suitable patients, hormone therapy may contribute to preventing bone loss. However, this decision is not based solely on bone density measurement. Long-term health planning should also consider the risk of falls and other preventive measures.
Cardiovascular health and metabolic monitoring
Early hormone loss, particularly after the removal of both ovaries at a young age, is a condition that needs to be evaluated in terms of long-term cardiovascular health. This does not mean that everyone will develop heart disease. Known risk factors such as blood pressure, blood sugar, blood lipids, smoking, and family history remain important. Reviewing these factors during postoperative follow-up is beneficial.
Hormone therapy should not be presented as a cure-all for heart disease in everyone. The assessment for hormone replacement therapy in early surgical menopause differs from initiating treatment in older women solely for heart protection. Age, time elapsed since menopause, and individual risks are all considered together. General health checkups and lifestyle adjustments are part of the treatment. The absence of symptoms does not mean that monitoring of blood pressure or metabolic risks is unnecessary.
Hormone replacement in surgical menopause treatment
Menopausal hormone therapy can be used to manage hot flashes and other symptoms in suitable patients. In individuals who experience surgical menopause at a young age and have no contraindications to treatment, not only the severity of symptoms but also the long-term effects of early hormone loss are considered. The British Menopause Society recommends that hormone therapy, particularly in cases of surgical menopause before age 45, be evaluated until the average age of natural menopause. This does not mean that everyone will receive the same treatment.
The type of treatment, route of administration, and dosage are individualized. Tablets, topical products, or local options for specific complaints have different characteristics. The patient's previous medical history, including blood clots, migraines, liver problems, and cancer history, should be discussed. Response and side effects are monitored after the prescription is initiated. Hormone therapy does not restore surgically removed ovaries or restore fertility; its aim is to manage the effects of hormone loss under appropriate conditions.
If there is a uterus, is progesterone needed?
Individuals using systemic estrogen and possessing a uterus usually also require a suitable progestogen to preserve the uterine lining. For those who have had their uterus completely removed, estrogen-only options may be considered. However, specific histories, such as endometriosis, or details regarding the scope of the surgery may alter the plan. Therefore, a definitive generalization such as "I don't have a uterus, so a single hormone is always sufficient" should not be made.
NICE menopause recommendations emphasize treatment selection based on uterine condition and expert opinion regarding comorbidities. Whether the product used is systemic or purely local vaginal treatment is also important; these are not evaluated in the same way. The patient should understand the purpose of each product prescribed. If unexpected bleeding occurs during treatment, the timing and the preparation used should be discussed with the healthcare team.
Who requires special evaluation for hormone therapy?
A history of hormone-sensitive cancer, unexplained vaginal bleeding, a history of clotting disorders, or certain liver and cardiovascular diseases can influence treatment decisions. These factors require individual assessment; a single list of allowances or prohibitions cannot be used to make decisions for all conditions. Planning with the oncology team is crucial in post-cancer care. The benefits, risks, and alternatives of treatment should be discussed in a way the patient can understand.
Different hormones, doses, and routes of administration carry different risks. It is not advisable to use a product that has worked well for someone else. Hormone mixtures obtained online or with unclear ingredients do not replace standard assessments. Terms like "bioequivalent" or "natural" alone do not guarantee safety. Patients should report all products they use to help identify interactions and avoid unnecessary repetition. It is important that treatment decisions are made in conjunction with monitoring.
Treatment after surgical menopause when hormone therapy is unsuitable
If hormone therapy is unsuitable or unwilling, symptomatic non-hormonal options can be considered. Menopause-adapted cognitive behavioral therapy, sleep management, and, in appropriate cases, some prescription medications may be considered. The choice depends on the predominant symptom, such as hot flashes, sleepiness, or mood. Not all of these methods have the same goals or effects.
Non-hormonal symptom treatment is not a single solution that replaces all the long-term effects of early hormone loss. Bone and general health monitoring should also be continued. The content, interactions, and safety of herbal products should also be evaluated. Indiscriminate use of these products is not appropriate, especially in individuals undergoing cancer treatment. Clearly communicating patient preferences allows for the establishment of a feasible treatment plan. Not seeking treatment does not eliminate the need for information and follow-up.
Vaginal dryness and sexual life
Decreased estrogen can cause vaginal dryness, burning, and discomfort during intercourse. Appropriate lubricants and moisturizers, as well as topical treatments if needed, can be considered. Treatment for vaginal dryness is planned based on the individual's history. Especially in cases of cancer history, topical hormone therapy options should also be evaluated by the relevant team. Continuing intercourse despite pain is not recommended.
Changes in sexual desire may not be solely dependent on hormone levels. The reason for surgery, body image, relationship dynamics, pain, and sleep can also play a role. Assessment of sexual dysfunction in women considers these factors together. Additional hormonal options may be considered in selected patients, but this is not standard for everyone. If pain persists during intercourse, other causes should also be investigated.
Should fertility plans be discussed before surgery?
Removing both ovaries is an irreversible procedure and affects a person's future pregnancy options with their own eggs. Therefore, if time and medical conditions permit, fertility aspirations should be openly discussed before surgery. In urgent or special cases, such as cancer treatment, the scope and timing of options may differ. This discussion is not to unnecessarily delay surgery, but to realistically evaluate the possible options.
Whether an ovarian-preserving approach is appropriate and fertility preservation options can be discussed with relevant specialists. Not every method is possible or suitable for everyone; success cannot be guaranteed. Hormone therapy after surgery does not restore egg production. It is important to ask the patient whether she wants children in the future, rather than assuming it. Having had children before does not mean that preferences in this matter are no longer important.
Emotional effects of surgical menopause
Post-operative relief can be accompanied by feelings of anxiety, sadness, or loss. Unexpected surgeries, cancer diagnoses, or changes in fertility options can make the process more difficult. Experiencing these emotions does not mean the person is weak. Support from close friends and family, and psychological help when needed, can be beneficial. It is important to consider that physical symptoms and emotional burden can influence each other.
If there is persistent depression, significant anxiety, or impairment in daily functioning, a professional evaluation may be sought. It is not accurate to attribute all mood changes solely to hormones. Sleep, pain, medications, and lifestyle factors are also considered. The patient should be given space to describe how they feel during follow-up appointments. The treatment plan should not be limited to prescribing medication; it should also support the individual's return to their daily life.
What is the post-operative follow-up process?
Initial check-ups cover surgical recovery, pathology results, and any new symptoms. Subsequent check-ups assess the effectiveness and side effects of hormone therapy, bone health, and overall risks. The frequency of follow-ups varies from person to person. It should not be assumed that the initiated treatment will continue in the same way for life; the plan is reviewed as age and health conditions change. The decision to continue treatment is also discussed individually when the average age of natural menopause is reached.
New vaginal bleeding, increased pain, or unexplained, significant symptoms may warrant prompting a follow-up appointment. Postoperative fever, wound problems, painful swelling in the leg, chest pain, or shortness of breath should not be considered signs of menopause. Serious findings require urgent evaluation. Keeping surgical and pathology reports facilitates the accurate transfer of information when the patient receives care at another center.
Questions that may be asked during a surgical menopause consultation
Before surgery, the patient can be asked which organs will be removed, the rationale for each procedure, and alternatives. Suitability for hormone therapy, fertility plans, expected symptoms, and long-term follow-up should also be discussed. How the approach might change if an unexpected finding arises during surgery can be part of the consent discussion. Having the patient explain any terms they don't understand strengthens the decision-making process.
Contact information for a personal consultation with Assoc. Prof. Dr. Nazlı Korkmaz is available. This content is based on resources from BMS, NICE, ACOG, and NHS. For a detailed framework, please consult the British Menopause Society's surgical menopause resource . General information is not a recommendation for personal surgery or hormone therapy; expected benefits and risks should be evaluated in conjunction with the reason for surgery, age, and medical history.
Frequently Asked Questions
Does having a uterus removed necessarily cause menopause?
No. If the ovaries are preserved, hormone production can continue. The cessation of menstruation alone does not mean menopause.
If one ovary is removed, will it result in surgical menopause?
The remaining ovary can continue to function. This is not the same as having both ovaries removed.
Can surgical menopause be reversed?
Removing both ovaries is an irreversible procedure. Hormone therapy will not restore the ovaries or egg production.
Does surgical menopause benefit everyone?
No. The expected benefit depends on the reason for the surgery. The risks of early hormone loss are also evaluated.
Can everyone use hormones?
No. Factors such as age, reason for surgery, and history of cancer and blood clots affect suitability.
If there is no uterus, is estrogen alone sufficient?
It may be suitable for some individuals. Different plans may be needed due to specific conditions such as endometriosis; an individual assessment will be conducted.
Does surgical menopause end sexual life?
No. Dryness, pain and changes in sexual desire can be assessed, and suitable support and treatment can be planned individually.
If there are no symptoms, is a check-up necessary?
Yes, especially in cases of early-onset hormone loss, bone and overall health needs should be assessed regardless of symptoms.